Literature DB >> 20527686

Immunotherapy. Significant overall survival advantage for RCC patients treated with autologous tumor lysate vaccine.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20527686     DOI： 10.1038/nrclinonc.2010.74

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting.

Authors:  Matthias May; Sabine Brookman-May; Bernd Hoschke; Christian Gilfrich; Friederike Kendel; Susann Baxmann; Stefan Wittke; Stephan T Kiessig; Kurt Miller; Manfred Johannsen
Journal:  Cancer Immunol Immunother       Date:  2009-10-30       Impact factor: 6.968
  1 in total
  1 in total

1.  Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Authors:  Chengkuan Cai; Jingyuan Tang; Baixin Shen; Liucheng Ding; Yunpeng Shao; Zhengsen Chen; Yinchao Ma; Haoliang Xue; Zhongqing Wei
Journal:  Exp Ther Med       Date:  2017-07-31       Impact factor: 2.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.